This technology can be used to treat a variety of genetic diseases that affect the CNS, such as lysosomal storage diseases (e.g. Tay-Sachs, Neimann-Pick, Sly's Disease). The technology may also be useful for treating other conditions that result from a biochemical deficiency in the CNS (e.g. ParkinsonÕs Disease, possibly AlzheimerÕs), or in which delivery of other gene products may be useful (e.g. delivery of cytokines).

U.S. Patent No. 7,402,308.

Wistar is seeking an exclusive license for this technology.